共查询到19条相似文献,搜索用时 234 毫秒
1.
《山东中医学院学报》2012,(1):80-80
日前,复旦大学附属华山医院吴志英教授和福建医科大学附属第一医院王柠教授领衔的科研团队,在运动障碍疾病研究中取得新突破。研究人员在8个家族性发作性运动诱发性运动障碍(PKD)家系中,发现PRRT2基因上存在3种截短突变,并成功克隆了家族性PKD的第一个致病基因PRRT2。 相似文献
2.
《山东中医药大学学报》2012,(1):80
<正>日前,复旦大学附属华山医院吴志英教授和福建医科大学附属第一医院王柠教授领衔的科研团队,在运动障碍疾病研究中取得新突破。研究人员在8个家族性发作性运动诱发性运动障碍(PKD)家系中,发现PRRT2基因上存在3种截短突变,并成功克隆了家族性PKD的第一个致病基因PRRT2。这一进展对充分理解该病的分子发病机制以及 相似文献
3.
4.
5.
6.
目的:探讨热性惊厥(FS)伴发作性运动诱发性运动障碍(PKD)的临床特征和遗传特点.方法:同顾性分析1例中国汉族FS伴PKD家系的临床资料,并进行文献复习.结果:共调查该家系41名成员,该家系有8例FS患者,5例PKD患者,其中2例FS患者伴发PKD.5例PKD患者均表现为静止状态下突然运动诱发的短暂不自主运动,神经系统查体均无异常;所有患者MRI/CT正常,3例脑电图异常,2例正常;抗癫药物治疗有效.结论:该家系诊断为复杂性PKD,呈不全外显性遗传,热性惊厥与发作性运动诱发性运动障碍可能有相关性. 相似文献
7.
发作性运动障碍[1](paroxysmal dyskinesia)是一类罕见的发作性疾病,特点是突然且反复发作的不自主动作,发作间期完全正常。诱发因素常为突然运动、惊吓、劳累或饮酒等。根据诱因、发作持续时间及病因等不同,可将本病分为四型:发作性运动诱发性运动障碍(PKD),发作性非运动诱发 相似文献
8.
目的:发作性运动诱发性运动障碍(PKD)的临床探析。方法:对2011年5月至2013年2月在我院经住院治疗的33例发作性诱发性运动障碍的患者进行临床分析并随诊。结果:发作性诱发性运动障碍患者在发作前都有显著的诱发因素,大多数是因突然运动(包括护理的翻身)、紧张、过度换气或惊吓而诱发的。发作性肌张力障碍、投掷运动、舞蹈样动作或手足徐动等,多为一侧性,持续时间1s至5min,发作频率为每周数次或每天10余次是该病的主要临床表现。在发病时意识清楚,发作间歇期完全正常。发病的平均年龄在4至17岁之间。在治疗过程中有初8例脑电图异常以外,其他的病例其电生理以及神经影像学检查无明确异常。卡马西平类药物对治疗发作性诱发性运动障碍有很好的疗效。结论:发作性运动诱发性运动障碍病是一种由运动诱发的、短暂的、发作性局部或全身不随意运动,属于离子通路疾病。用抗癫痫药疗效好。该病最好的、最准确的治疗方案是发作性运动障碍的准确分类。 相似文献
9.
发作性运动障碍(PDs)是一组相对少见、遗传异质性短暂、发作性异常运动综合征,目前公认的有三种形式,包括发作性运动诱发运动障碍、发作性非运动诱发运动障碍和发作性持续运动诱发运动障碍。随着对其病理生理学和遗传学的深入认识,将会对基于家族性病例的基因型-表型关联性作出更好的临床分类。现从其分类、临床表现、遗传学、病理生理学及治疗方面对三种原发性PDs的最新进展予以综述。 相似文献
10.
11.
Ke XU Shan-shan HUANG Dao-yuan YUE Guo LI Sui-qiang ZHU Xiao-yan LIU 《华中科技大学学报(医学英德文版)》2022,(2):280-285
Objective:Paroxysmal kinesigenic dyskinesia(PKD)is a rare movement disorder.PRRT2 gene mutations have been reported to cause PKD.However,the pathophysiological ... 相似文献
12.
扩张型心肌病是一种以左心室和/或右心室扩大、心肌收缩功能受损为主要特征的心肌疾病,是除冠心病和高血压以外导致心力衰竭的主要病因之一。家族性扩张型心肌病约占扩张型心肌病的35%。目前为止,发现的和扩张型心肌病相关的基因突变主要是心肌蛋白基因突变和细胞骨架蛋白基因突变,此外还有线粒体DNA的突变和能量代谢相关的基因突变。本文对引起家族性扩张型心肌病的分子遗传进展进行了总结。 相似文献
13.
14.
家族性急性髓系白血病相关新基因ELF2C cDNA全长的克隆 总被引:1,自引:0,他引:1
目的克隆家族性急性髓系白血病相关新基因全长,在分子水平上探讨急性白血病发生发展的机制。方法以构建的家族性急性髓系白血病抑制性?肖减性文库中1个有差异表达的新基因EST序列(zywb4)为基础,综合应用电子克隆和cDNA末端快速扩增法(RACE)技术克隆家族性急性髓系白血病相关新基因的全长cDNA。结果获得家族性急性髓系白血病差异表达新基因ELF2C的全长cDNA和432bp的开放阅读框(ORF),Blast检索为一功能未知基因,被GenBank收录,注册号为DQ359746。结论成功获得一个家族性急性髓系白血病相关新基因ELF2CcDNA全长,为进一步研究其功能提供了依据。 相似文献
15.
Background Hepatitis B virus (HBV) x protein (HBx) in HepG2 cells causes a moderate decrease in proteolysis activity of the proteasome. A highly conserved Kunitz-type serine protease inhibitor domain within 154 amino acid residues of HBx has been identified. In this study, a peptide chain derived from the Kunitz domain (PKD) was used to study its effect on the cell cycle and apoptosis of HepG2 cells, and investigated the function of PKD on the activities of proteasomes and AAA-ATPase p97, which involves in the ubiquitin-proteasome protein degradation pathway.
Methods The PKD peptide (Phe-Val-Leu-Gly-Gly-Cys-Arg-His-Lys) was chemically synthesized. MTT assays were used to determine the effects of PKD on HepG2 cell growth. Mouse anti-p97 antibody was developed for Western blotting to detect the expression of p97. ATPase activity of proteasomes was measured using a colorimetric assay. Peptidase activities of proteasomes were analyzed with various peptidase-specific fluorogenic peptide substrates. Flow cytometry was used to determinate cell cycle phase and apoptosis.
Results Viability of HepG2 cells decreased in a PKD-dose-dependent manner. Cells exhibited significant cytotoxicity in the presence of 15 mmol/L of PKD. Western blotting analysis showed that expression of p97 was suppressed in HepG2 cells treated with PKD compared to untreated cells. The ATPase activity of proteasomes from immunoprecipitates of HepG2 cells pretreated with PKD was apparently decreased. Chymotryptic activity of proteasomes in HepG2 cells was significantly inhibited by 10mmol/L PKD; tryptic activity and peptidylglutamyl peptide hydroiase activity of proteasomes were less inhibited by PKD than chymotryptic activity. The cell cycle phase of HepG2 cells treated with PKD for 36 hours was blocked largely at the G0-G1 phase, while untreated control cells were mainly in S phase. PKD also significantly induced apoptosis.
Conclusions The peptide derived from Kunitz domain of HBx protein induces HepG2 cell growth arrest and apoptosis, which may result from down-regulation of p97 expression, and decrease of both the ATPase and chymotryptic activities of proteasomes. 相似文献
Methods The PKD peptide (Phe-Val-Leu-Gly-Gly-Cys-Arg-His-Lys) was chemically synthesized. MTT assays were used to determine the effects of PKD on HepG2 cell growth. Mouse anti-p97 antibody was developed for Western blotting to detect the expression of p97. ATPase activity of proteasomes was measured using a colorimetric assay. Peptidase activities of proteasomes were analyzed with various peptidase-specific fluorogenic peptide substrates. Flow cytometry was used to determinate cell cycle phase and apoptosis.
Results Viability of HepG2 cells decreased in a PKD-dose-dependent manner. Cells exhibited significant cytotoxicity in the presence of 15 mmol/L of PKD. Western blotting analysis showed that expression of p97 was suppressed in HepG2 cells treated with PKD compared to untreated cells. The ATPase activity of proteasomes from immunoprecipitates of HepG2 cells pretreated with PKD was apparently decreased. Chymotryptic activity of proteasomes in HepG2 cells was significantly inhibited by 10mmol/L PKD; tryptic activity and peptidylglutamyl peptide hydroiase activity of proteasomes were less inhibited by PKD than chymotryptic activity. The cell cycle phase of HepG2 cells treated with PKD for 36 hours was blocked largely at the G0-G1 phase, while untreated control cells were mainly in S phase. PKD also significantly induced apoptosis.
Conclusions The peptide derived from Kunitz domain of HBx protein induces HepG2 cell growth arrest and apoptosis, which may result from down-regulation of p97 expression, and decrease of both the ATPase and chymotryptic activities of proteasomes. 相似文献
16.
目的 克隆家族性急性髓系白血病(AML)相关新基因cDNA全长,在分子水平上探讨急性白血病发生发展的机制.方法 以构建的家族性AML抑制性消减文库中1个有差异表达的新基因EST序列zywb87(GenBank注册号CV973101)为基础,应用cDNA末端快速扩增法(RACE)克隆其全长cDNA,应用生物信息学对其功能进行初步分析,应用一步法半定量RT-PCR检测其在AML患者及正常人中的表达.结果 获得了家族性AML相关新基因FAMLF的cDNA全长,该基因定位于染色体lq31.3,cDNA全长2313 bp,开放读码框(ORF)为249 bp,编码82个氨基酸的蛋白质,含有信号肽,富含亮氨酸重复单位(LRR_SD22),内在固有无序结构域等功能区.Blast检索为功能未知的新基因,已被GenBank收录,并命名为FAMLF,核酸注册号为EF413001,蛋白质注册号为ABN58747.新基因FAMLF在AML患者中的表达明显高于正常人,差异有统计学意义(2.61±0.66 vs 0.97±0.51,P<0.01).结论 成功获得一个家族性AML相关新基因FAMLF cDNA全长,FAMLF基因在AML中高表达,可能是具有一定生物功能的新基因. 相似文献
17.
目的 :观察 PK D2基因在正常人和 2型常染色体显性遗传性多囊肾病 (ADPKD)患者肾组织中的不同表达 ,探讨多囊肾病的发病机制。 方法 :抽提正常人肾组织细胞总 RNA ,通过 RT- PCR法获得 PK D 2基因第 12~ 13外显子 c DNA片段 ,以此为探针 ,用地高辛标记 ,对正常人和 2型 ADPKD患者肾组织分别进行原位杂交 ,并结合图像分析系统观察 PK D2基因表达情况。 结果 :正常人肾组织中 PK D2基因在 Henle襻的厚升支、远曲小管和皮质集合管有较强的表达 (平均光密度为 1.2 3± 0 .0 4 ) ;而 2型ADPKD患者肾组织中 PKD2基因仅在部分囊壁中有少量表达 (平均光密度为 0 .5 6± 0 .0 3)。 结论 :正常人肾组织中 PK D2基因表达量明显高于 2型 ADPKD患者 ,提示 PK D2基因表达降低在 2型 ADPKD的发生和发展中起着一定的作用 相似文献
18.
19.